Drug Trial Radar · NCT00758524
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Jul 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
628
Actual
Start
Sep 11, 2008
Primary completion
Jul 2, 2009
Study completion Jul 2, 2009
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.
Conditions
- Essential Hypertension
Interventions
LCI699Drug
LCI699 oral capsules
EplerenoneDrug
Eplerenone oral capsules
LCI699-matching PlaceboDrug
LCI699-matching placebo oral capsules
Eplerenone-matching PlaceboDrug
Eplerenone-matching placebo oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)Time frame: Baseline, Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Pharmaceuticals
East Hanover, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.